Shree Ganesh Remedies Ltd
Shree Ganesh Remedies Ltd Q3 FY26 Results & Presentation Highlights: Revenue ₹21.11 Cr, PAT ₹3.10 Cr
Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Shree Ganesh Remedies Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q3FY26 Revenue from Operations: ₹21.11 Cr - Q3FY25 Revenue from Operations: ₹27.05 Cr - Year-on-Year (YoY) change in Q3FY26 revenue: -22% - Management states Q3FY26 impact due to shipment delays (~10-12% deferment), challenging demand in Europe, and price competition. Q3FY26 EBITDA: ₹6.73 Cr, down 32% YoY - Q3FY26 Operating Margin (EBITDA %): 31.9%, down 471 bps YoY - Q3FY26 Profit After Tax (PAT): ₹3.10 Cr, down 43% YoY - Explicit margin outlook: - Mana
From Shree Ganesh Remedies Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3FY26 Revenue from Operations: ₹21.11 Cr
- Q3FY25 Revenue from Operations: ₹27.05 Cr
- Year-on-Year (YoY) change in Q3FY26 revenue: -22%
- Management states Q3FY26 impact due to shipment delays (~10-12% deferment), challenging demand in Europe, and price competition.
- Revenue recognition deferred mostly to Q4FY26.
- FY26 termed a "year of consolidation" with focus on execution and capability-building over aggressive growth.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Shree Ganesh Remedies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ankleshwar Site:
- Block 8 completed Capex in FY25.
- Block 7 Capex projected at ~₹20 Crores; ₹15 Crores outlay planned in FY26.
- Block 7 commissioning expected H1FY27.
- New Pilot Plant commissioned & operational (Q4FY26 automation & flow chemistries implementation planned).
- Dahej Land Acquisition:
- 40,554 sq m acquired in 2022; ₹11 Crores spent on land acquisition.
- Construction of common infrastructure and warehousing underway.
- Expansion to be phased; multiple projects evaluated (customer details under NDA).
- R&D Infrastructure:
- New R&D block planned for pilot trials and scale-ups (timeline not explicit).
- Overall Focus:
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Shree Ganesh Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Shree Ganesh Remedies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹33 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Shree Ganesh Remedies Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Anuh Pharma Ltd (Q3 FY26)
Q3 FY26 Revenue: ₹201.18 Cr (page 13: Operating Revenue 197.18 + possibly rounding difference clarified on page 6 as ₹201 Cr) . Key investor presentation takeaw
- Bharat Parenterals Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations (Consolidated): ₹65.2 crore, down 10% YoY from ₹72.3 crore in Q3 FY25 (Page 9). Key investor presentation takeaways from Bharat
- Themis Medicare Ltd (Q3 FY26)
90.13 Cr, a 3.9% decline year-on-year from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q3 FY26 investor presentation — and how it ranks a
- Kopran Ltd (Q3 FY26)
2,804 lakhs (~16.87% increase) . Key investor presentation takeaways from Kopran Ltd's Q3 FY26 investor presentation — and how it ranks against sector peers.
Frequently Asked Questions
What were Shree Ganesh Remedies Ltd Q3 FY26 results?
Q3FY26 Revenue from Operations: ₹21.11 Cr - Q3FY25 Revenue from Operations: ₹27.05 Cr - Year-on-Year (YoY) change in Q3FY26 revenue: -22% - Management states Q3FY26 impact due to shipment delays (~10-12% deferment), challenging demand in Europe, and price competition. Q3FY26 EBITDA: ₹6.73 Cr, down 32% YoY - Q3FY26 Operating Margin (EBITDA %): 31.9%, down 471 bps YoY - Q3FY26 Profit After Tax (PAT): ₹3.10 Cr, down 43% YoY - Explicit margin outlook: - Mana
What is Shree Ganesh Remedies Ltd share price analysis?
Shree Ganesh Remedies Ltd currently shows a neutral. The stock trades at a P/E of 58.0 with a market cap of ₹896 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shree Ganesh Remedies Ltd planning capital expenditure?
Ankleshwar Site: - Block 8 completed Capex in FY25.
Keep Shree Ganesh Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.